Katharine Hsu, PhD, MD

Publications

118

4 grants

PI
Weill Cornell/Rockefeller/Sloan Kettering MST Program
National Institute of General Medical Sciences · 2024–2029Training
T32GM152349-03
PI
Innate & Adaptive Determinants of Post-CAR Cytokine Release Syndrome
NCI · 2026–2028 · via NIH RePORTER
R21CA301202-01A1
PI
HCMV-induced innate-like CD8 T cells and allogeneic HCT outcome
NIAID · 2021–2027 · via NIH RePORTER
R01AI150999-05
PI
Machine learning with immunogenetics for the prediction of hematopoietic cell transplant outcomes
NHLBI · 2021–2025 · via NIH RePORTER
R01HL155741-04

Completed grants (10)

MPI
Weill Cornell/Rockefeller/Sloan Kettering MST Program
National Institute of General Medical Sciences · 2019–2024Training
T32GM007739-45
MPI
Project 3: NK and T cell cooperation in CMV infection
NCI · 1997–2024 · via NIH RePORTER
P01CA023766-41
PI
KIR and HLA in cis and trans cooperatively shape human NK education
NIAID · 2016–2022 · via NIH RePORTER
R01AI125651-05
PI
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA Genotypes
NHLBI · 2015–2022 · via NIH RePORTER
R01HL129472-05
PI
Phase I study humanized 3F8 MoAb (IND 112594) and NK cells (IND BB-13399) for neuroblastoma
NIH · 2016–2020 · via NIH RePORTER
R01FD005415-03
PI
Natural killer cell and T-cell crosstalk in CMV infection
NIAID · 2017–2019 · via NIH RePORTER
R56AI123658-01A1
PI
Combination immunotherapy for neuroblastoma: model of innate tumor immunity
NCI · 2012–2016 · via NIH RePORTER
R01CA164365-03
PI
Phase 1 Study of Immunotherapy with NK Cells anti-GD2 for Neuroblastoma
NIH · 2012–2015 · via NIH RePORTER
R01FD004128-03
PI
NK Tolerance and Hematopoietic Cell Transplantation
NHLBI · 2007–2014 · via NIH RePORTER
R01HL088134-05
PI
NK Receptors and Bone Marrow Transplant Outcome
NHLBI · 2004–2009 · via NIH RePORTER
K23HL070053-05

The Tri-Institutional M.D.-Ph.D. Program Celebrates 50 Years of Excellence
April 13, 2023
The program's enduring goal during the past half century has been to create the next generation of leaders in biomedical research.
Dr. Katharine Hsu Named Director of Tri-Institutional M.D.-Ph.D. Program
April 9, 2021
Dr. Katharine Hsu, an esteemed physician-scientist who specializes in immunology research and treatment of blood cancers, has been named director of the Tri-Institutional M.D.-Ph.D. Program, a joint program between Weill Cornell Medicine, The Rockefeller University and Memorial Sloan Kettering Cancer Center.
Dr. Katharine Hsu Wins Weill Cornell Graduate School Alumni Award
May 30, 2019
Dr. Katharine Hsu, M.D. ’94, Ph.D. ’93, professor of medicine and attending physician at Memorial Sloan Kettering Cancer Center, has been awarded the Weill Cornell Graduate School Alumni Award of Distinction.